X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ELDER PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ELDER PHARMA ASTRAZENECA PHARMA/
ELDER PHARMA
 
P/E (TTM) x 156.2 -0.2 - View Chart
P/BV x 24.3 0.1 24,028.4% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ASTRAZENECA PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
ELDER PHARMA
Jun-14
ASTRAZENECA PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs1,285380 338.2%   
Low Rs634188 337.2%   
Sales per share (Unadj.) Rs189.6491.2 38.6%  
Earnings per share (Unadj.) Rs-0.2-3.2 6.4%  
Cash flow per share (Unadj.) Rs3.814.4 26.7%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs68.6376.5 18.2%  
Shares outstanding (eoy) m25.0020.54 121.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.10.6 875.3%   
Avg P/E ratio x-4,712.7-89.3 5,279.5%  
P/CF ratio (eoy) x249.619.7 1,266.2%  
Price / Book Value ratio x14.00.8 1,853.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m23,9885,833 411.2%   
No. of employees `0001.6NA-   
Total wages/salary Rs m1,6052,179 73.6%   
Avg. sales/employee Rs Th3,040.2NM-  
Avg. wages/employee Rs Th1,029.2NM-  
Avg. net profit/employee Rs Th-3.3NM-  
INCOME DATA
Net Sales Rs m4,74010,089 47.0%  
Other income Rs m92257 35.9%   
Total revenues Rs m4,83210,346 46.7%   
Gross profit Rs m-130-792 16.4%  
Depreciation Rs m101361 28.0%   
Interest Rs m02,756 0.0%   
Profit before tax Rs m-139-3,653 3.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1393,713 3.7%   
Tax Rs m5125 4.1%   
Profit after tax Rs m-5-65 7.8%  
Gross profit margin %-2.7-7.8 34.9%  
Effective tax rate %-3.7-3.4 107.0%   
Net profit margin %-0.1-0.6 16.6%  
BALANCE SHEET DATA
Current assets Rs m2,7269,240 29.5%   
Current liabilities Rs m2,4359,998 24.4%   
Net working cap to sales %6.1-7.5 -81.9%  
Current ratio x1.10.9 121.1%  
Inventory Days Days7446 159.3%  
Debtors Days Days4160 68.0%  
Net fixed assets Rs m1,03510,124 10.2%   
Share capital Rs m50206 24.3%   
"Free" reserves Rs m9425,582 16.9%   
Net worth Rs m1,7167,734 22.2%   
Long term debt Rs m04,889 0.0%   
Total assets Rs m4,15622,882 18.2%  
Interest coverage xNM-0.3-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.10.4 258.7%   
Return on assets %-0.111.8 -1.0%  
Return on equity %-0.3-0.8 35.1%  
Return on capital %022.3 0.0%  
Exports to sales %5.73.0 187.6%   
Imports to sales %6.50.4 1,512.8%   
Exports (fob) Rs m270307 88.1%   
Imports (cif) Rs m30643 710.7%   
Fx inflow Rs m375307 122.2%   
Fx outflow Rs m470125 375.2%   
Net fx Rs m-96181 -52.7%   
CASH FLOW
From Operations Rs m-811,754 -0.1%  
From Investments Rs m-146-561 26.0%  
From Financial Activity Rs m862-6,762 -12.8%  
Net Cashflow Rs m7094,432 16.0%  

Share Holding

Indian Promoters % 0.0 39.6 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 7.5 4.0%  
FIIs % 15.7 16.8 93.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 36.1 25.2%  
Shareholders   12,856 16,479 78.0%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   DR. REDDYS LAB  STERLING BIOTECH  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Remains Rangebound; HDFC AMC & Reliance Nippon Tumble Over 8%(12:30 pm)

Stock markets in India are trading in a range with positive bias in the afternoon session amid firm cues in the Asian markets and a recovery in rupee. Gains are largely seen in metal stocks and energy stocks.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 212.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Sep 19, 2018 01:23 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS